Renal dopamine D1 receptor dysfunction is acquired and not inherited in obese Zucker rats

American Journal of Physiology - Renal Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Banday, Anees Ahmad ^a   Hussain, Tahir ^a   Lokhandwala, Mustafa F ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

G proteins; Insulin; Na K ATPase; Obesity; Rosiglitazone

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DOPAMINE; DOPAMINE 1 RECEPTOR; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY PROXIMAL TUBULE; LEAN BODY WEIGHT; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 2942657679     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00396.2003     Document Type: Article

References (52)

1. Alonso-Galicia Brands MW, Zappe DH, and Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28: 1047-1054, 1996.
2. Banday AA, Asghar M, Hussain T, and Lokhandwala MF. Dopamine-mediated inhibition of renal Na,K-ATPase is reduced by insulin. Hypertension 41: 1353-1358, 2003.
3. Berg FM (Editor). Special report: health risks of obesity. In: Obesity, and Health (2nd ed.). Hettinger, NC: Healthy Living Institute, 1993.
4. Bickel CA, Verbalis JG, Knepper MA, and Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and β-ENaC abundance in obese Zucker rats. Am J Physiol Renal Physiol 281: F639-F648, 2001.
5. Blazer-Yost BL, Esterman MA, and Viahos CJ. Insulin-stimulated trafficking of ENaC in renal cells requires PI 3-kinase activity. Am J Physiol Cell Physiol 284: C1645-C1653, 2003.
6. Blazer-Yost BL, Liu X, and Helman SI. Hormonal regulation of ENaCs: insulin and aldosterone. Am J Physiol Cell Physiol 274: C1373-C1379, 1998.
7. Bray GA. The Zucker-fatty rats: a review. Federation Proc 36: 148-153, 1997.
8. Carlson SH, Shelton J, White R, and Wyss MJ. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. Hypertension 35: 403-408, 2000.
9. Chen C, Beach RE, and Lokhandwala MF. Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats. Hypertension 21: 364-372, 1993.
10. Chen CJ and Lokhandwala MF. Inhibition of Na,K-ATPase in renal proximal tubule by dopamine involves DA-1 receptor activation. Naunyn Schmiedebergs Arch Pharmacol 347: 289-295, 1993.
11. Chua SC Jr, White DW, Wu-Peng XS, Liu SM, Okada N, Kershaw EE, Chung WK, Power-Kehoe L, Chua M, Tartaglia LA, and Leibel RL. Phenotype of fatty due to Gln269pro mutation in the leptin receptor (Lepr). Diabetes 45: 1141-1143, 1996.
12. Felder CC, Blecher M, and Jose PA. Dopamine-1 mediated stimulation of phospholipase C activity in rat renal cortical membranes. J Biol Chem 264: 8739-8745, 1989.
13. Felder CC, Campbell T, Albrecht F, and Jose PA. Dopamine inhibits Na-H exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol Renal Fluid Electrolyte Physiol 259: F297-F303, 1990.
14. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, and Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 99: 3872-3877, 2002.
15. Felder RA, Seikaly MG, Cody P, and Jose PA. Attenuated renal response to dopaminergic drugs in spontaneously hypertensive rats. Hypertension 15: 560-569, 1990.
16. Fujiwara K, Hayashi K, Matsuda H, Kubota E, Honda M, Ozawa Y, and Saruta T. Altered pressure-natriuresis in obese Zucker rats. Hypertension 33, Suppl: S1470-S1475, 1999.
17. Garrison RJ, Kannel WB, Stokes J III, and Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16: 234-251, 1987.
18. Hall JE. The kidney, hypertension and obesity. Hypertension 41: 625-633, 2003.
19. Hall JE, Kuo JJ, Da Silva AA, De Paula RB, Liu J, and Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 12: 195-200, 2003.
20. Hegde SS, Jadhav AL, and Lokhandwala MF. Role of kidney dopamine in the natriuretic response to volume expansion in rats. Hypertension 13: 828-834, 1989.
21. Hilbert P, Lindpaintner L, Beckman JS, Serikawa T, Soubrier F, Dubay C, Cartwright P, De Gouyon B, Julier C, Takahasi S, Vincent M, Ganten D, Georges M, and Lathrop GM. Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature 353: 521-529, 1991.
22. Hussain T, Becker M, Beheray S, and Lokhandwala MF. Dopamine fails to inhibit Na, H-Exchanger in proximal tubules of obese Zucker rats. Clin Exp Hypertens 23: 591-601, 2001.
23. Hussain T, Beheray SA, and Lokhandwala MF. Defective dopamine receptor function in proximal tubules of obese Zucker rats. Hypertension 34: 1091-1096, 1999.
24. q/11 proteins in spontaneously hypertensive rats. Am J Physiol Renal Physiol 272: F339-F346, 1997.
25. Hussain T and Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 32: 187-197, 1998.
26. Jose PA, Raymond JR, Bates MD, Aperia A, Felder RA, and Carey RM. The renal dopamine receptors. J Am Soc Nephrol 2: 1265-1278, 1992.
27. + transport. Am J Physiol Renal Physiol 283: F377-F387, 2002.
28. Kasiske BL, O'Donnell MP, and Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1, Suppl: I110-I115, 1992.
29. Kramer D, Shapiro R, Adler A, Bush E, and Rondinone CM. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 11: 1294-1300, 2001.
30. Kurtz TW. Genetics of essential hypertension. Am J Med 94: 77-84, 1993.
31. Kurtz TW, Morris RC, and Pershadsing HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13: 896-901, 1989.
32. Morgan DA, Anderson EA, and Mark AL. Renal sympathetic nerve activity is increased in obese Zucker rats. Hypertension 25: 834-838, 1995.
33. Oberkofler H, Neschen S, Esterbauer H, Waldhausl W, Patsch W, and Furnsinn C. UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats. Biochim Biophys Acta 1517: 113-118, 2000.
34. Pelayo JC, Fildes RD, Eisner GM, and Jose PA. Effects of dopamine blockade on renal sodium excretion. Am J Physiol Renal Fluid Electrolyte Physiol 245: F247-F253, 1983.
35. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, and Hess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13: 18-19, 1996.
36. Record RD, Froelich L, Vlahos CJ, and Blazer-Yost BL. Phosphatidylinositol 3-kinase activation is required for insulin stimulated sodium transport in A6 cells. Am J Physiol Endocrinol Metab 274: E611-E617, 1998.
37. Rosenberg MR and Michalopoulos G. Kidney proximal tubular cells isolated by collagenase perfusion grow in defined media in the absence of growth factors. J Cell Physiol 131: 107-113, 1987.
38. Sanada H, Jose PA, Hazen-Martin D, Yu P, Xu J, Bruns DE, Phipps J, Carey RM, and Felder RA. Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 33: 1036-1042, 1999.
39. Segers O, Anckaert E, Gerlo E, Dupont AG, and Somers G. Dopamine-sodium relationship in type 2 diabetes patients. Diabetes Res Clin Prac 34: 89-98, 1996.
40. Segers O, Dupont AG, Gerlo E, and Somers G. Urinary sodium and dopamine excretion. 2. Role of hyperinsulinemia in renal dopamine production. Med Sci Res 24: 571-572, 1996.
41. Soweres JR, Soweres PS, and Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 123: 647-652, 1994.
42. +-ATPase by insulin: why and how? Mol Cell Biochem 182: 121-133, 1998.
43. Tack CJJ, Lutterman JA, Vervoort G, Thien T, and Smiths P. Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension 28: 426-432, 1996.
44. 1 receptor blockade or angiotensin-converting enzyme inhibition in obese Zucker rats. Clin Exp Pharmacol Physiol 28: 433-440, 2001.
45. Terrettaz J and Jeanrenaud B. In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology 36: 148-153, 1983.
46. Therien AG and Blostein R. Mechanism of sodium pump regulation. Am J Physiol Cell Physiol 279: C541-C566, 2000.
47. Umrani DU, Banday AA, Hussain T, and Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension 40: 880-885, 2002.
48. Vyas SJ, Eichberg J, and Lokhandwala MF. Characterization of receptors involved in dopamine-induced activation of phospholipase C in rat renal cortex. J Pharmacol Exp Ther 260: 134-139, 1992.
49. Walker AB, Chattington PD, Buckingham RE, and Williams G. The thiozolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453, 1999.
50. + exchanger interactions in the kidney in hypertension. Hypertension 36: 395-399, 2000.
51. 2+ handling in the aorta of Zucker obese rats with insulin resistance. Diabetes 45, Suppl: S55-S58, 1996.
52. Yen TT, Yu P, Roeder H, and Willard PW. A genetic study of hypertension in Okamoto-Aoki spontaneously hypertensive rats. Heredity 33: 309-316, 1974.